Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: Design of the RAVE trial

American Heart Journal

Volumn 145, Issue 6, 2003, Pages 1114-1118

  Rajagopalan, Sanjay ^a   Mohler III, Emile ^b   Lederman, Robert J ^c   Saucedo, Jorge ^d   Mendelsohn, Farrell O ^e   Olin, Jeffrey ^f   Blebea, John ^g   Goldman, Corey ^h   Trachtenberg, Jeffrey D ⁱ   Pressler, Milton ^j   Rasmussen, Henrik ^k   Annex, Brian H ^l   Hirsch, Alan T ^m  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^e Baptist Princeton Medical Center   (United States)

^f Heart and Vascular Institute of New Jersey   (United States)

^g PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^h Watson Clinic   (United States)

ⁱ Decatur Memorial Hospital   (United States)

^j PFIZER INC   (United States)

^k GenVec   (United States)

^l DUKE UNIVERSITY   (United States)

^m UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS GENE VASCULAR ENDOTHELIAL GROWTH FACTOR 121; ADENOVIRUS VECTOR; BIO BYPASS; ENDOTHELIAL CELL GROWTH FACTOR; ISOPROTEIN; UNCLASSIFIED DRUG; LYMPHOKINE; SIGNAL PEPTIDE; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROSIS; CLINICAL RESEARCH; CLINICAL TRIAL; COLLATERAL CIRCULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DOPPLER FLOWMETRY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVALUATION; EXERCISE TEST; FEMORAL ARTERY; HUMAN; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; LIMB PERFUSION; LOW DRUG DOSE; METHODOLOGY; MULTICENTER STUDY; OUTCOMES RESEARCH; PARAMETER; PHASE 2 CLINICAL TRIAL; PHYSICAL DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; TECHNIQUE; TREADMILL; VIRAL GENE DELIVERY SYSTEM; WALKING; ADENOVIRUS; GENE TRANSFER; GENE VECTOR; GENETICS; MIDDLE AGED; PATIENT SELECTION;

ADENOVIRIDAE; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; ENDOTHELIAL GROWTH FACTORS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERMITTENT CLAUDICATION; LYMPHOKINES; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PATIENT SELECTION; RESEARCH DESIGN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0038281504     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00102-9     Document Type: Article

References (21)

1. Isner JM. Myocardial gene therapy. Nature 2002;415:234-9.
2. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002;136:54-71.
3. Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994;93:662-70.
4. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999;103:1231-6.
5. Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 2000;102:e73-86.
6. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia [comments]. Circulation 1998;97:1114-23.
7. Rajagopalan S, Trachtenberg J, Mohler E III, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol 2002;90:512-6.
8. Cooper LT, Hiatt WR, Creager MA, et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med 2001;4:235-9.
9. Tea H. Final results for the VIVA trial of rhVEGF for human therapeutic angiogenesis. Circulation 1999;100:A2509.
10. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.
11. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication: the TRAFFIC study. Lancet 2002;359:2053-8.
12. Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998;28:964-75.
13. Magovern CJ, Mack CA, Zhang J, et al. Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther 1997;8:215-27.
14. Mack CA, Magovern CJ, Budenbender KT, et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 1998;27:699-709.
15. Smith RA, Mettlin CJ, Davis KJ, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2000;50:34-49.
16. Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical trials for claudication: assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation 1995;92:614-21.
17. Anonymous. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5 Suppl):786-806.
18. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.
19. Lederman RJ, Tenaglia AN, Anderson RD. Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial. Am J Cardiol 2001;88:192-5, A6-7.
20. Hiatt WR, Regensteiner JG, Hargarten ME, et al. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990;81:602-9.
21. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-75.